Blood oxygen level-dependent MRI for evaluation of early response of liver tumors to chemoembolization: An animal study

Anticancer Research

Volumn 33, Issue 5, 2013, Pages 1887-1892

  Choi, Jin Woo ^a   Kim, Hyeonjin ^b   Kim, Hyo Cheol ^a   Lee, Yunjung ^b   Kwon, Jeongmin ^b   Yoo, Roh Eul ^a   Cho, Hye Rim ^a   Choi, Seung Hong ^a   Chung, Jin Wook ^a  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Blood oxygen level dependent MRI; Chemoembolization; Hepatocellular carcinoma

Indexed keywords

CARBOGEN;

AMBIENT AIR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BOLD SIGNAL; BREATHING; CANCER TRANSPLANTATION; CHEMOEMBOLIZATION; LIVER CELL CARCINOMA; LIVER TUMOR; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; RAT;

BLOOD OXYGEN LEVEL-DEPENDENT MRI; CHEMOEMBOLIZATION; HEPATOCELLULAR CARCINOMA;

ANIMALS; CARBON DIOXIDE; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DISEASE MODELS, ANIMAL; IMAGE PROCESSING, COMPUTER-ASSISTED; LIVER NEOPLASMS, EXPERIMENTAL; MAGNETIC RESONANCE IMAGING; OXYGEN; RADIATION-SENSITIZING AGENTS; RATS; RATS, SPRAGUE-DAWLEY; TUMOR CELLS, CULTURED;

EID: 84878201294     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Bruix J, Sherman M and American Association for the Study of Liver Disease: Management of hepatocellular carcinoma: An update. Hepatology 53(3): 1020-1022, 2011.
2. Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet 379(9822): 1245-1255, 2012.
3. Kang SG, Yoon CJ, Jeong SH, Kim JW, Lee SH, Lee KH and Kim YH: Single-session combined therapy with chemoembolization and radiofrequency ablation in hepatocellular carcinoma less than or equal to 5 cm: a preliminary study. J Vasc Interv Radiol 20(12):1570-1577, 2009.
4. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N and Geschwind JF: Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 29(30): 3960-3967, 2011.
5. Cheng BQ, Jia CQ, Liu CT, Fan W, Wang QL, Zhang ZL and Yi CG: Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: A randomized controlled trial. JAMA 299(14): 1669-1677, 2008. (Pubitemid 351519864)
6. Ogawa S, Lee TM, Kay AR and Tank DW: Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acd Sci USA 87(24): 9868-9872, 1990. (Pubitemid 120016545)
7. Kwong KK, Belliveau JW, Chesler DA, Goldberg IE, Weisskoff RM, Poncelet BP, Kennedy DN, Hoppel BE, Cohen MS and Turner R: Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acd Sci USA 89(12): 5675-5679, 1992.
8. Davis TL, Kwong KK, Weisskoff RM and Rosen BR: Calibrated functional MRI: Mapping the dynamics of oxidative metabolism. Proc Natl Acd Sci USA 95(4): 1834-1839, 1998. (Pubitemid 28103480)
9. Dunn JF, O'Hara JA, Zaim-Wadghiri Y, Lei H, Meyerand ME, Grinberg OY, Hou H, Hoopes PJ, Demidenko E and Swartz HM: Changes in oxygenation of intracranial tumors with carbogen: A BOLD MRI and EPR oximetry study. J Magn Reson Imaging 16(5): 511-521, 2002. (Pubitemid 35257757)
10. Hoskin PJ, Carnell DM, Taylor NJ, Smith RE, Stirling JJ, Daley FM, Saunders MI, Bentzen SM, Collins DJ, d'Arcy JA and Padhani AP: Hypoxia in prostate cancer: Correlation of BOLDMRI with pimonidazole immunohistochemistry- initial observations. Int J Radiat Oncol Biol Phys 68(4): 1065-1071, 2007. (Pubitemid 47048571)
11. Taylor NJ, Baddeley H, Goodchild KA, Powel ME, Thoumine M, Culver LA, Stirling JJ, Saunders MI, Hoskin PJ, Philips H, Padhani AR and Griffiths JR: BOLD MRI of human tumor oxygenation during carbogen breathing. J Magn Reson Imaging 14(2): 156-163, 2001. (Pubitemid 32709475)
12. Gallez B, Baudelet C and Jordan BF: Assessment of tumor oxygenation by electron paramagnetic resonance: Principles and applications. NMR Biomed 17(5): 240-262, 2004. (Pubitemid 39268771)
13. Figueiras RG, Padhani AR, Goh VJ, Vilanova JC, Gonzalez SB, Martin CV, Caamano AG, Naveira AB and Choyke PJ: Novel oncologic drugs: What they do and how they affect images. Radiographics 31(7): 2059-2091, 2011.
14. Rodrigues LM, Howe FA, Griffiths JR and Robinson SP: Tumor R2*is a prognostic indicator of acute radiotherapeutic response in rodent tumors. J Magn Reson Imaging 19(4): 482-488, 2004. (Pubitemid 38437157)
15. Guo Y, Jin N, Klein R, Nicolai J, Yang GY, Omary RA and Larson AC: Gas challenge-blood oxygen level-dependent (GC-BOLD) MRI in the rat Novikoff hepatoma model. Magn Reson Imaging 30(1): 133-138, 2012.
16. Cho HR, Choi JW, Kim HC, Song YS, Kim GM, Son KR and Chung JW: Sprague-Dawley rats bearing McA-RH7777 cells for study of hepatoma and transarterial chemoembolization. Anticancer Res 33(1): 223-230, 2013.
17. Hsu YY, Chang CN, Jung SM, Lim KE, Huang JC, Fang SY and Liu HL: Blood oxygenation level-dependent MRI of cerebral gliomas during breath holding. J Magn Reson Imaging 19(2):160-167, 2004.
18. Thomas CD, Chenu E, Walczak C, Plessis MJ, Perin F and Volk A: Relationship between tumour growth rate and carbogen-based functional MRI for a chemically induced HCC in mice. MAGMA 17: 271-280, 2004. (Pubitemid 40362310)
19. Dunn TJ, Braun RD, Rhemus WE, Rosner GL, Secomb TW, Tozer GM, Chaplin DJ and Dewhirst MW: The effects of hyperoxic and hypercarbic gases on tumour blood flow. Br J Cancer 80: 117-126, 1999. (Pubitemid 29210097)
20. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J and EASL Panel of Experts on HCC: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3): 421-430, 2001.
21. Lencioni R and Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52-60, 2010.
22. Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS and Suh DJ: Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 262(2): 708-718, 2012.
23. Georgiades C, Geschwind JF, Harrison N, Hines-Peralta A, Liapi E, Hong K, Wu Z, Kamel I and Frangakis C: Lack of response after initial chemoembolization for hepatocellular carcinoma: Does it predict failure of subsequent treatment? Radiology 265:115-123, 2012.
24. Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW and Taouli B: Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: Diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol 193(4): 1044-1052, 2009.
25. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA and Geschwind JF: Unresectable hepatocellular carcinoma: Serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 250(2): 466-473, 2009.
26. Powell ME, Collingridge DR, Saunders MI, Hoskin PJ, Hill SA and Chaplin DJ: Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations. Radiother Oncol 50(2): 167-171, 1999. (Pubitemid 29155542)
27. Barash H, Gross E, Matot I, Edrei Y, Tsarfaty G, Spira G, Vlodavsky I, Galun E and Abramovitch R: Functional MR imaging during hypercapnia and hyperoxia: Noninvasive tool for monitoring changes in liver perfusion and hemodynamics in a rat model. Radiology 243(3): 727-735, 2007. (Pubitemid 46799426)
28. Fan Z, Elzibak A, Boylan C and Noseworthy MD: Blood oxygen level-dependent magnetic resonance imaging of the human liver: Preliminary results. J Comput Assist Tomogr 34(4): 523-531, 2010.
29. Haque M, Koktzoglou I, Li W, Carbray J and Prasad P: Functional MRI of liver using BOLD MRI: Effect of glucose. J Magn Reson Imaging 32(4): 988-991, 2010.